A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)

被引：1
|
作者：
Mirza, M. R. [1 ,2 ]
Monk, B. J. [3 ]
Oza, A. [4 ]
Mahner, S. [5 ,6 ]
Redondo, A. [7 ,8 ]
Fabbro, M. [9 ,10 ]
Ledermann, J. [11 ,12 ]
Lorusso, D. [13 ,14 ]
Vergote, I. B. [15 ,16 ]
Rosengarten, O. [17 ,18 ]
Berek, J. [19 ]
Herrstedt, J. [20 ,21 ]
Tinker, A. V. [22 ]
Dubois, A. [23 ,24 ]
Gonzalez Martin, A. [25 ,26 ]
Follana, P. [27 ,28 ]
Benigno, B. [29 ]
Rimel, B. J. [30 ]
Agarwal, S. [31 ]
Matulonis, U. [32 ]
机构：
[1] NSGO, Dept Oncol 5073, Copenhagen, Denmark
[2] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
[3] Univ Arizona, Canc Ctr Phoenix, Dept Oncol, Phoenix, AZ USA
[4] Univ Hlth Network, Dept Oncol, Toronto, ON, Canada
[5] AGO, Dept Gynegol, Hamburg, Germany
[6] Univ Munich, Hamburg, Germany
[7] GEICO, Dept Oncol, Madrid, Spain
[8] Univ Hosp, Madrid, Spain
[9] GINECO, Dept Oncol, Montpellier, France
[10] Inst Canc Montpellier, Montpellier, France
[11] NCRI, Dept Med Oncol, London, England
[12] UCL, London, England
[13] MITO MaNGO, Dept Gynecol Oncol, Milan, Italy
[14] Fdn IRCCS Natl Canc Inst, Milan, Italy
[15] BGOG, Dept Obstet & Gynecol, Leuven, Belgium
[16] Univ Leuven, Leuven, Belgium
[17] ISGO, Dept Gynecol Oncol, Jerusalem, Israel
[18] Shaare Zedek Med Ctr, Jerusalem, Israel
[19] Stanford Womens Canc Ctr, Dept Oncol, Stanford, CA USA
[20] NSGO, Dept Oncol, Odense, Denmark
[21] Odense Univ Hosp, Odense, Denmark
[22] British Columbia Canc Agcy, Dept Med, Vancouver, BC, Canada
[23] AGO, Dept Oncol, Essen, Germany
[24] Kliniken Essen Mitte, Essen, Germany
[25] GEICO, Med Oncol Dept, Madrid, Spain
[26] MD Anderson Canc Ctr Madrid, Madrid, Spain
[27] GINECO, Dept Med Oncol, Nice, France
[28] Ctr Antoine Lacassagne, Nice, France
[29] Univ Gynecol Oncol, Dept Gynecol Oncol, Atlanta, GA USA
[30] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, West Hollywood, CA USA
[31] Tesaro Inc, Dept Med Affairs, Waltham, MA USA
[32] Dana Farber Canc Inst, Dept Gynecol Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw435.26
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA3_PR
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer
    Qiu, Yijin
    Zha, Jingkai
    Ma, Aixia
    Zhou, Ting
    GYNECOLOGIC ONCOLOGY, 2023, 174 : 175 - 181
  • [42] Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ ENGOT-ov38): a phase IIIb trial
    Pujade-Lauraine, E.
    Selle, F.
    Scambia, G.
    Asselain, B.
    Marme, F.
    Lindemann, K.
    Colombo, N.
    Madryl, R.
    Glasspool, R.
    Vergote, I.
    Korach, J.
    Lheureux, S.
    Dubot, C.
    Oaknin, A.
    Zamagni, C.
    Heitz, F.
    Gladieff, L.
    Rubio-Perez, M. J.
    Scollo, P.
    Blakeley, C.
    Shaw, B.
    Ray-Coquard, I
    Redondo, A.
    ANNALS OF ONCOLOGY, 2023, 34 (12) : 1152 - 1164
  • [43] ENGOT-OV-6/TRINOVA-2: RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN PLUS TREBANANIB OR PLACEBO IN WOMEN WITH RECURRENT PARTIALLY PLATINUM-SENSITIVE OR RESISTANT OVARIAN CANCER
    Marth, C.
    Vergote, I.
    Colombo, N.
    Kurzeder, C.
    Lorusso, D.
    Clamp, A.
    Berger, R.
    Vuylsteke, P.
    Scambia, G.
    Wenham, R.
    Mirza, M. R.
    Fong, P. C.
    Hall, M.
    Kristeleit, R.
    Oza, A.
    Monk, B.
    Zhang, K.
    Vogl, F. D.
    Bach, B. A.
    Altintas, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 97 - 99
  • [44] Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): fi nal overall survival analysis of a phase 3 randomised, placebo-controlled trial
    Wu, Xiaohua
    Zhu, Jianqing
    Yin, Rutie
    Yang, Jiaxin
    Liu, Jihong
    Wang, Jing
    Wu, Lingying
    Liu, Ziling
    Gao, Yunong
    Wang, Danbo
    Lou, Ge
    Yang, Hongying
    Zhou, Qi
    Kong, Beihua
    Huang, Yi
    Chen, Lipai
    Li, Guiling
    An, Ruifang
    Wang, Ke
    Zhang, Yu
    Yan, Xiaojian
    Lu, Xin
    Lu, Weiguo
    Hao, Min
    Wang, Li
    Cui, Heng
    Chen, Qionghua
    Abulizi, Guzhalinuer
    Huang, Xianghua
    Tian, Xiaofei
    Wen, Hao
    Huang, Zhao
    Dong, Juan
    Zhang, Charlie
    Hou, Jianmei
    Mirza, Mansoor R.
    ECLINICALMEDICINE, 2024, 72
  • [45] ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
    Marth, Christian
    Vergote, Ignace
    Scambia, Giovanni
    Oberaigner, Willi
    Clamp, Andrew
    Berger, Regina
    Kurzeder, Christian
    Colombo, Nicoletta
    Vuylsteke, Peter
    Lorusso, Domenica
    Hall, Marcia
    Renard, Vincent
    Pignata, Sandro
    Kristeleit, Rebecca
    Altintas, Sevilay
    Rustin, Gordon
    Wenham, Robert M.
    Mirza, Mansoor Raza
    Fong, Peter C.
    Oza, Amit
    Monk, Bradley J.
    Ma, Haijun
    Vogl, Florian D.
    Bach, Bruce A.
    EUROPEAN JOURNAL OF CANCER, 2017, 70 : 111 - 121
  • [46] Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial (vol 18, pg 1274, 2017)
    Pujade-Lauraine, E.
    Ledermann, J. A.
    Selle, F.
    LANCET ONCOLOGY, 2017, 18 (09): : E510 - E510
  • [47] A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
    Shi, Tingyan
    Yin, Sheng
    Zhu, Jianqing
    Zhang, Ping
    Liu, Jihong
    Zhu, Yaping
    Wu, Sufang
    Chen, Xiaojun
    Wang, Xipeng
    Teng, Yincheng
    Zhu, Tao
    Yu, Aijun
    Zhang, Yingli
    Feng, Yanling
    Huang, He
    Bao, Wei
    Li, Yanli
    Jiang, Wei
    Li, Jiarui
    Ai, Zhihong
    Zhang, Wei
    Jia, Huixun
    Zhang, Yuqin
    Jiang, Rong
    Zhang, Jiejie
    Gao, Wen
    Luan, Yuting
    Zang, Rongyu
    Xiang, Libing
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2020, 31 (03)
  • [48] Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
    Ledermann, Jonathan A.
    Harter, Philipp
    Gourley, Charlie
    Friedlander, Michael
    Vergote, Ignace
    Rustin, Gordon
    Scott, Clare
    Meier, Werner
    Shapira-Frommer, Ronnie
    Safra, Tamar
    Matei, Daniela
    Fielding, Anitra
    Spencer, Stuart
    Rowe, Philip
    Lowe, Elizabeth
    Hodgson, Darren
    Sovak, Mika A.
    Matulonis, Ursula
    LANCET ONCOLOGY, 2016, 17 (11): : 1579 - 1589
  • [49] A randomized double-blind phase II trial evaluating maintenance PARP inhibitor Olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer: PIPSeN trial
    Postel-Vinay, S.
    Planchard, D.
    Granados, A. L. Ortega
    Gazzah, A.
    Gonzalez, M. A. Sala
    Majem, M.
    Camps, C. J.
    Abou-Lauvergne, A.
    Pignon, J-P.
    Cadranel, J.
    Bennouna, J.
    Barlesi, F.
    Campelo, M. R. Garcia
    Viteri, S.
    Besse, B.
    Sarto, J. Coves
    Sureda, B. Massuti
    Soria, J-C.
    Rosell, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] THE ENGOT-OV26/PRIMA PHASE 3 TRIAL: NIRAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OVARIAN CANCER WHO RESPONDED TO FRONT-LINE PLATINUM-BASED THERAPY
    Gonzalez Martin, A.
    Rojas, L. A.
    Braly, P.
    Barter, J.
    O'Malley, D. M.
    Oza, A.
    Haggerty, A.
    Vulsteke, C.
    Provencher, D.
    Graybill, W.
    Li, Y.
    Malinowska, I. A.
    Mirza, M. R.
    Vergote, I.
    Pothuri, B.
    Monk, B. J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1510 - 1510
12345